Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Signatures with ICS in COPD by Eosinophil Level
2023-505245-13-00Phase 4Authorised
- Sponsor
- IDIBAPS
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 4 trial of budesonide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by IDIBAPS. Primary endpoint: Primary molecular changes with ICS vs usual care stratified by eosinophils. Planned start Jul 2024; status: authorised.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2023-505245-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505245-13-00.